PRVB - Provention Bio: Oversold Territory An Attractive Buying Opportunity
- Provention Bio is oversold, and the stock is trading at an attractive price level. I expect a sharp rebound shortly.
- The key question is "when" will Teplizumab be approved, not whether Teplizumab will be approved or not.
- Teplizumab approval will likely be delayed, and I expect the approval to take place during 1H 2022.
- I am cautiously optimistic based on the FDA's willingness to discuss CMC issues concurrently with its ongoing review.
- Uncertainty remains as both the company and the FDA did not provide investors clear guidance.
For further details see:
Provention Bio: Oversold Territory, An Attractive Buying Opportunity